Federal Register #FDA2026N4492

FDA Request for Information on Drug Repurposing for Unmet Medical Needs

The Food and Drug Administration (FDA), under the Department of Health and Human Services, is seeking public input on drug repurposing for unmet medical needs. - Government Buyer: - Department of Health and Human Services (HHS) - Food and Drug Administration (FDA) - Purpose: - Request for Information (RFI) to gather comments, data, and information on FDA-approved drugs that lack commercial interest for new uses via supplemental applications - Focused on identifying opportunities to repurpose existing drugs for conditions with unmet medical needs - OEMs and Vendors: - No specific Original Equipment Manufacturers (OEMs) or vendors are named, as this is an information-gathering effort - Products/Services Requested: - No procurement of products or services; the FDA is only requesting stakeholder feedback and information - Unique/Notable Requirements: - The FDA is establishing a public docket to collect broad stakeholder input - The opportunity is not for procurement but for gathering information to inform future FDA actions on drug repurposing - No product or service line items are included

Description

The Food and Drug Administration (FDA) is extending the comment period for its notice titled "Drug Repurposing for Unmet Medical Needs; Request for Information" originally published on May 12, 2026. The FDA is soliciting input on its efforts related to drug repurposing to address unmet medical needs, focusing on FDA-approved drugs with no commercial interest for new uses. This extension allows interested parties additional time to submit comments until July 13, 2026. Comments can be submitted electronically or in writing to the FDA docket.

View original listing